Rhumbline Advisers Sells 20,902 Shares of Moderna, Inc. (NASDAQ:MRNA)

Rhumbline Advisers cut its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 3.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 525,003 shares of the company’s stock after selling 20,902 shares during the period. Rhumbline Advisers owned about 0.14% of Moderna worth $21,830,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Wilmington Savings Fund Society FSB raised its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the period. Blue Trust Inc. raised its stake in shares of Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after purchasing an additional 388 shares during the period. EMC Capital Management raised its stake in shares of Moderna by 311.2% during the 4th quarter. EMC Capital Management now owns 1,250 shares of the company’s stock worth $52,000 after purchasing an additional 946 shares during the period. Finally, Larson Financial Group LLC raised its stake in shares of Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Performance

Shares of MRNA stock opened at $33.73 on Friday. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The stock has a 50 day moving average price of $38.17 and a two-hundred day moving average price of $53.20. The company has a market capitalization of $12.98 billion, a P/E ratio of -3.63 and a beta of 1.59.

Insider Activity at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 2,664 shares of company stock worth $115,210 over the last quarter. 15.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. UBS Group lowered their target price on Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday. The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a report on Monday, November 18th. Finally, Barclays lowered Moderna from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $111.00 to $45.00 in a report on Tuesday. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Moderna presently has a consensus rating of “Hold” and an average target price of $60.63.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.